Compare New York Times Co (NYT) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? New York Times Co trades at $66.32 (market cap $10.74B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.73 (market cap $58.74B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 5.5× New York Times Co's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold New York Times Co for 81 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| NYT | TAK | |
|---|---|---|
Market Cap | $10.74B | $58.74B |
Volume | 2,096,352 | 3,110,994 |
Sector | Media | Health |
52-Week High | $85.86 | $19.05 |
52-Week Low | $54.66 | $13.23 |
Typical Hold Time | 81 Days | 1 Days |
Enterprise Value | $10.14B | $86.65B |
Dividend Yield | 1.38% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYT) trades at $66.32, up 2.19% today, with strong fundamental performance including consistent earnings beats and revenue growth from $2.3B in 2022 to $2.8B in 2025. The stock shows a bullish technical signal with key support at $65-66 and resistance at $67-68, while maintaining robust profitability with 51.41% gross margins and 13.19% net income margin. Recent developments include a declared $0.23 dividend and ongoing AI copyright litigation.
Outlook remains positive with analyst consensus target of $84 representing 27% upside potential, though risks include the shareholder lawsuit alleging bias and competitive pressures in digital media. The company's strong cash flow generation and dividend payments provide shareholder value, while earnings growth trajectory supports continued valuation expansion if execution remains solid.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
